- Home
- PHAR vs ACP Comparison
PHAR vs ACP Comparison
Compare PHAR & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ACP
- Stock Information
- Founded
- PHAR 1988
- ACP 2010
- Country
- PHAR Netherlands
- ACP United States
- Employees
- PHAR N/A
- ACP N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- PHAR Health Care
- ACP Finance
- Exchange
- PHAR Nasdaq
- ACP Nasdaq
- Market Cap
- PHAR 798.2M
- ACP 737.8M
- IPO Year
- PHAR N/A
- ACP N/A
- Fundamental
- Price
- PHAR $13.70
- ACP $5.89
- Analyst Decision
- PHAR Strong Buy
- ACP
- Analyst Count
- PHAR 3
- ACP 0
- Target Price
- PHAR $30.00
- ACP N/A
- AVG Volume (30 Days)
- PHAR 12.8K
- ACP 337.9K
- Earning Date
- PHAR 07-31-2025
- ACP 01-01-0001
- Dividend Yield
- PHAR N/A
- ACP 17.79%
- EPS Growth
- PHAR N/A
- ACP N/A
- EPS
- PHAR N/A
- ACP N/A
- Revenue
- PHAR $339,836,000.00
- ACP N/A
- Revenue This Year
- PHAR $12.88
- ACP N/A
- Revenue Next Year
- PHAR $8.54
- ACP N/A
- P/E Ratio
- PHAR N/A
- ACP N/A
- Revenue Growth
- PHAR 22.44
- ACP N/A
- 52 Week Low
- PHAR $6.73
- ACP $5.55
- 52 Week High
- PHAR $17.08
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- ACP 40.59
- Support Level
- PHAR $12.13
- ACP $5.94
- Resistance Level
- PHAR $12.76
- ACP $5.99
- Average True Range (ATR)
- PHAR 0.89
- ACP 0.03
- MACD
- PHAR 0.13
- ACP -0.01
- Stochastic Oscillator
- PHAR 44.41
- ACP 11.74
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.